AU2015262415B2 - Method for monomerizing matrix metalloproteinase-7 (MMP-7) aggregate - Google Patents

Method for monomerizing matrix metalloproteinase-7 (MMP-7) aggregate Download PDF

Info

Publication number
AU2015262415B2
AU2015262415B2 AU2015262415A AU2015262415A AU2015262415B2 AU 2015262415 B2 AU2015262415 B2 AU 2015262415B2 AU 2015262415 A AU2015262415 A AU 2015262415A AU 2015262415 A AU2015262415 A AU 2015262415A AU 2015262415 B2 AU2015262415 B2 AU 2015262415B2
Authority
AU
Australia
Prior art keywords
mmp
composition
solution
monomerization
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015262415A
Other languages
English (en)
Other versions
AU2015262415A1 (en
Inventor
Masaki Hirashima
Reiko Matsuyama
Wataru Morikawa
Hiroshi Nakatake
Hideki Takeo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KM Biologics Co Ltd
Original Assignee
KM Biologics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KM Biologics Co Ltd filed Critical KM Biologics Co Ltd
Publication of AU2015262415A1 publication Critical patent/AU2015262415A1/en
Assigned to KM BIOLOGICS CO., LTD. reassignment KM BIOLOGICS CO., LTD. Request for Assignment Assignors: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Application granted granted Critical
Publication of AU2015262415B2 publication Critical patent/AU2015262415B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24023—Matrilysin (3.4.24.23)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2015262415A 2014-05-21 2015-05-20 Method for monomerizing matrix metalloproteinase-7 (MMP-7) aggregate Active AU2015262415B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014105452 2014-05-21
JP2014-105452 2014-05-21
PCT/JP2015/064451 WO2015178414A1 (ja) 2014-05-21 2015-05-20 マトリックスメタロプロテアーゼ７（ｍｍｐ－７）会合体の単量体化方法

Publications (2)

Publication Number Publication Date
AU2015262415A1 AU2015262415A1 (en) 2016-12-01
AU2015262415B2 true AU2015262415B2 (en) 2021-04-01

Family

ID=54554080

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015262415A Active AU2015262415B2 (en) 2014-05-21 2015-05-20 Method for monomerizing matrix metalloproteinase-7 (MMP-7) aggregate

Country Status (11)

Country Link
US (2) US10774321B2 (ko)
EP (1) EP3147358A4 (ko)
JP (1) JP6755793B2 (ko)
KR (1) KR102286557B1 (ko)
CN (1) CN106536731A (ko)
AU (1) AU2015262415B2 (ko)
CA (1) CA2949238C (ko)
MX (2) MX2016015187A (ko)
RU (1) RU2724543C2 (ko)
TW (1) TWI743023B (ko)
WO (1) WO2015178414A1 (ko)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194189B1 (en) * 1994-12-16 2001-02-27 Washington University Catalytically-active gelatinase mutant

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2938352B2 (ja) 1994-09-30 1999-08-23 オリエンタル酵母工業株式会社 組換え人マトリライシンの製造方法
JP3937192B2 (ja) 1997-04-03 2007-06-27 東洋紡績株式会社 新規な糖化蛋白質および該物質を用いた分析用試薬
JP4507027B2 (ja) 1998-12-04 2010-07-21 明治乳業株式会社 Ｍｍｐ阻害剤
FR2788525B1 (fr) * 1999-01-19 2002-11-29 Commissariat Energie Atomique Pseudo-peptides phosphiniques, utilisables comme inhibiteurs des metalloproteases a zinc matricielles
JP4521894B2 (ja) 1999-05-28 2010-08-11 明治乳業株式会社 マトリックスメタロプロテアーゼ阻害剤
JP4813652B2 (ja) 2000-12-04 2011-11-09 丸善製薬株式会社 マトリックスメタロプロテアーゼ阻害剤
US7148046B2 (en) 2001-04-02 2006-12-12 Astex Therapeutics Limited Crystal structure of cytochrome P450
MXPA04002368A (es) * 2001-09-12 2005-07-25 Virexx Res Inc Agente de fase solida para la oclusion vascular con un agente enlazante de plaquetas inmovilizado.
US20050164341A1 (en) 2002-05-30 2005-07-28 Jose Cosme Methods of purification of cytochrome p450 proteins and of their crystallizing
JP4512038B2 (ja) 2002-12-25 2010-07-28 小森 博達 椎間板変性治療剤
JP2005006509A (ja) 2003-06-16 2005-01-13 Arkray Inc メタロプロテアーゼの保存方法、および前記方法を用いたメタロプロテアーゼ試薬溶液
US20060099567A1 (en) 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
JP2008206491A (ja) * 2007-02-28 2008-09-11 Toyobo Co Ltd ｐ−ヒドロキシ安息香酸水酸化酵素の安定化方法
AU2009307423B2 (en) * 2008-10-21 2014-05-08 Km Biologics Co., Ltd. Process for producing protein capable of forming inclusion body
ES2582459T3 (es) * 2010-02-04 2016-09-13 Biomarin Pharmaceutical Inc. Composiciones de variantes de fenilalanina amoníaco-liasa de procariotas y métodos de uso de sus composiciones
AU2012261813B2 (en) * 2011-06-02 2017-04-20 Takeda Pharmaceutical Company Limited Formulations of recombinant furin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194189B1 (en) * 1994-12-16 2001-02-27 Washington University Catalytically-active gelatinase mutant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KANNAN R et al., "Purification of active matrix metalloproteinase catalytic domains and its use for screening of specific stromelysin-3 inhibitors", Protein Expr. Purif., (1999), vol. 16, no. 1, ISSN 1046-5928, pages 76 - 83 *
LOPEZ DE TURISO J et al., "Expression and purification of human matrilysin produced in baculovirus-infected insect cells", J. Biotechnol., (1996), vol. 46, no. 3, ISSN 0168-1656, pages 235 - 241 *

Also Published As

Publication number Publication date
RU2724543C2 (ru) 2020-06-23
WO2015178414A1 (ja) 2015-11-26
EP3147358A4 (en) 2017-12-06
JP6755793B2 (ja) 2020-09-16
CA2949238A1 (en) 2015-11-26
RU2016150091A (ru) 2018-06-22
US10774321B2 (en) 2020-09-15
MX2021001285A (es) 2021-04-28
RU2016150091A3 (ko) 2019-01-24
AU2015262415A1 (en) 2016-12-01
KR102286557B1 (ko) 2021-08-04
KR20170003665A (ko) 2017-01-09
BR112016027089A2 (pt) 2017-10-17
US20200140843A1 (en) 2020-05-07
TWI743023B (zh) 2021-10-21
EP3147358A1 (en) 2017-03-29
CA2949238C (en) 2023-05-02
TW201625788A (zh) 2016-07-16
CN106536731A (zh) 2017-03-22
MX2016015187A (es) 2017-07-27
JPWO2015178414A1 (ja) 2017-04-20
US20170081654A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
US8173397B2 (en) Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
JP6045642B2 (ja) プラスミノーゲンを製造するための組成物、方法およびキット；ならびにそれから製造されるプラスミン
CN110093336B (zh) 一种稳定的胰蛋白酶及其制备方法
AU2015262415B2 (en) Method for monomerizing matrix metalloproteinase-7 (MMP-7) aggregate
US7335758B2 (en) Catalytic domain of ADAM33 and methods of use thereof
KR101634078B1 (ko) 봉입체 형성 단백질의 제조방법
BR112016027089B1 (pt) Método para monomerização de agregados de matriz metaloproteinase 7 (mmp-7), composição farmacêutica compreendendo mmp-7 e seu uso para tratamento de deslocamento de disco intervertebral e processo para preparação de mmp-7
JP3095787B2 (ja) ＩＸａ因子の触媒活性の測定方法
DK2813567T3 (en) C-terminally bound amino acids and their therapeutic fibrinolytic applications
JP2008514194A (ja) 組み換えカルボキシペプチダーゼｂ

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: KM BIOLOGICS CO., LTD.

Free format text: FORMER APPLICANT(S): THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE

FGA Letters patent sealed or granted (standard patent)